Skip to main content

Security report for novavax.com

Novavax · Healthcare · United States

Low risk. 3 critical or high findings in SSL/TLS and Security headers.

Security score

78/100

Risk levelLow

0–100, higher is better. How it is calculated

Novavax is a biotechnology company specializing in vaccine development using proprietary technology platforms such as Matrix-M adjuvant and protein-based nanoparticles. The company targets unmet medical needs with a strong pipeline and strategic partnerships to maximize impact in global health. The website reflects a mature digital presence with comprehensive content aimed at investors, partners, and healthcare professionals. Technically, the site is built on Drupal 10 with modern JavaScript libraries and includes robust privacy and cookie consent mechanisms. Security posture is strong with HTTPS, security headers, and no visible vulnerabilities, though a dedicated security policy and incident response contacts are not published. Overall, the site is professional, trustworthy, and well-optimized for performance and accessibility.

Scanned

NIS2 and GDPR posture

GDPR outside view
88/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1
    • High

      Weak SSL Key Length

      SSL certificate uses 256-bit key, which is considered weak

      What to do: Use at least 2048-bit RSA or 256-bit ECC key

      • CWE-326
      • OWASP A04:2025
      • Mozilla TLS: Mozilla Server Side TLS 6.0 intermediate: rsa_key_size 2048

  2. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

Need hands-on remediation? Email guard@offseq.com

Keep watching novavax.com

This scan found 17 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
54
Security headers
55
Email security
85
DNS health
85
Network security
100
GDPR outside view
88
Average
78

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Novavax operates in the healthcare sector with a focus on vaccine R&D and commercialization. Its business model leverages proprietary technology and partnerships to develop vaccines for diseases like COVID-19, influenza, malaria, and others. The company maintains a strong investor relations presence and regularly publishes financial results and scientific insights. The presence of a subsidiary in Sweden indicates international operations. The company targets healthcare providers, governments, and global health organizations as primary customers. Growth is supported by ongoing pipeline advancement and strategic collaborations.

Security posture

The website demonstrates a good security maturity level with enforced HTTPS, multiple security headers, and a cookie consent mechanism compliant with GDPR. No exposed sensitive data or vulnerable libraries were detected. However, the absence of a published security policy, incident response information, or vulnerability disclosure program limits transparency and readiness perception. There is no visible security.txt file. Overall, the site is secure but could improve by publishing formal security governance documents and contact channels for security incidents.

Recommendations

  1. Publish a dedicated security policy page outlining security practices and compliance.
  2. Provide clear incident response contact information such as security@ or abuse@ email addresses.
  3. Implement and publish a vulnerability disclosure program or security.txt file to encourage responsible reporting.
  4. Regularly audit and update third-party libraries to avoid potential vulnerabilities.
  5. Enhance transparency by including data retention policies and detailed privacy compliance statements.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Novavax
Description
Novavax is a biotech company with a proven technology, focused on developing R&D assets and establishing partnerships to help protect health.
Key services
Vaccine development, Research and development, Partnerships for health protection
Content quality
excellent
Branding
consistent

Technology

Stack
Drupal 10, jQuery, Google Tag Manager, AOS (Animate On Scroll), AddToAny, OneTrust Cookie Consent
Frameworks
Drupal CMS
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Use of security headers
  • Cookie consent mechanism implemented
  • No exposed sensitive data detected

Analytics and tracking

Services
Google Tag Manager
Tracking level
moderate
Privacy practices
good

Advertising

Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content and multimedia
  2. Strong focus on biotech and vaccine development
  3. Clear navigation and professional design
  4. Use of modern web technologies and compliance tools
  5. No signs of malicious or suspicious activity
  6. WHOIS data unavailable, which is unusual but not necessarily suspicious for a corporate site
Technical notes

Notes

The website is built on Drupal 10 CMS, leveraging modern JavaScript libraries including jQuery and AOS for animations. Google Tag Manager is used for analytics and marketing tags. The site is mobile responsive with good accessibility features and SEO optimization. Performance is moderate, with multimedia content and external scripts potentially impacting load times. The use of OneTrust for cookie consent indicates compliance with privacy regulations. Hosting provider details are not explicit. Overall, the technical infrastructure is modern and well-maintained, supporting a professional user experience.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with novavax.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review novavax.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.